Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

36.20
-1.1158-2.99%
Post-market: 36.200.00000.00%16:10 EDT
Volume:2K
Turnover:58.29K
Market Cap:7.24M
PE:- -
High:37.39
Open:37.39
Low:36.20
Close:37.31
52wk High:43.01
52wk Low:25.42
Shares:200.00K
Float Shares:200.00K
Volume Ratio:0.95
T/O Rate:0.80%
Dividend:0.32
Dividend Rate:0.89%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Scholar Rock says FDA requested pregnancy safety study for Isembyld

TIPRANKS
·
3 hours ago

Scholar Rock Shares Fall After Barclays Downgrade

MT Newswires Live
·
4 hours ago

Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says

MT Newswires Live
·
4 hours ago

Scholar Rock Holding Price Target Raised to $70.00/Share from $64.00 by Wedbush

Dow Jones
·
Yesterday

Scholar Rock Holding Corporation : H.c. Wainwright Raises Target Price to $70 from $65

THOMSON REUTERS
·
Yesterday

Brain-Computer Breakthrough Enables Paralysed Individuals to Communicate Through Digital Avatars

Deep News
·
Yesterday

Market Playbook: Key Bullish and Bearish Signals for Stocks on September 15, 2026

Deep News
·
Yesterday

Scholar Rock downgraded to Equal Weight from Overweight at Barclays

TIPRANKS
·
Yesterday

Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook

Reuters
·
Yesterday

Scholar Rock Says Its First Muscle-Targeted SMA Therapy Will Cost About $310,000 Annually

Reuters
·
Sep 14

Scholar Rock Holding Price Target Maintained with a $64.00/Share by Wedbush

Dow Jones
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

Scholar Rock Exec Says Its First Drug to Target Muscle Loss in Spinal Mus­Cu­Lar at­Ro­Phy Has a Wholesale Acquisition Cost of $11,659 for a Single Use Vial - Conf.call

THOMSON REUTERS
·
Sep 14

Scholar Rock Exec Says Co Expects the Annual Net Cost in the U.S. for a Typical Patient to be Approximately $310,000

THOMSON REUTERS
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Top Premarket Gainers

MT Newswires Live
·
Sep 14

Truist Raises Price Target on Scholar Rock Holding to $76 From $55, Keeps Buy Rating

MT Newswires Live
·
Sep 14

Scholar Rock Shares up 11.6% Premarket After FDA Nod for First Muscle-Targeted Drug for Type of Genetic Disease

THOMSON REUTERS
·
Sep 14

Scholar Rock Holding Corporation : Citigroup Raises Target Price to $74 from $60

THOMSON REUTERS
·
Sep 14

Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14